Author Index Vol. 61, 2001
Terence Chuen-Wai Poon, Johan Lundin(University of Helsinki), Kyoko Iwao, Ch. Kouroussis, Thomas W. T. Leung(Chinese University of Hong Kong), John Dervenoulas(National and Kapodistrian University of Athens), Sofia Agelaki(University of Crete), N. Androulakis, N. Vardakis, Marja Leivonen, Rainer Fietkau(Friedrich-Alexander-Universität Erlangen-Nürnberg), S. Kakolyris, Michelle Ghert(University of Maryland, Baltimore), Dimitra Rontogianni(Evangelismos Hospital), Scott D. Jewell(Van Andel Institute), Harold Erickson(Duke Medical Center), Dimitris Kalantzis, Stig Nordling, Susanne Markmann, Toralf Reimer(University of Rostock), Panagiotis Tsirigotis, Benny Zee(Chinese University of Hong Kong), G. Bollas, Tony Mok(Chinese University of Hong Kong), V. Georgoulias, Mythily Srinivasan(Indiana University – Purdue University Indianapolis), Sung Taek Jung, Yasuo Miyoshi(The Cancer Institute Hospital), John Souglakos(University of Crete), Eichi Shiba, Anna Koumarianou(University General Hospital Attikon), Anthony T.�C. Chan(Chinese University of Hong Kong), Joel A. Block(Rush University Medical Center), K. Kalbakis, Stephen King-Wah Ho, Heiner Müller(Unknown), Bernd Gerber(Universitäts Frauenklinik), E. Papageorgiou(National and Kapodistrian University of Athens), Wen‐Ning Qi, Georgios Mantzios, S. Raptis(National and Kapodistrian University of Athens), Sean P. Scully, L. Vamvakas, Philip Johnson, John M. Harrelson(Duke University), Shinzaburo Noguchi(Hyogo Prefectural Nishinomiya Hospital), Chiyomi Egawa, D. Mavroudis, Annette Krause, Theofanis Economopoulos(University General Hospital Attikon)
Cited by 0
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k